Molecular changes in pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1487-1497

  Buchholz, Malte ^a   Gress, Thomas M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Cellular origin; Molecular alterations; Mouse models; Pancreatic cancer; Preneoplastic lesions

Indexed keywords

CHOLECYSTOKININ RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GASTRIN; K RAS PROTEIN; MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER GROWTH; CARCINOGENESIS; CELL TRANSFORMATION; GENETIC DISORDER; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MUTATION; NONHUMAN; PANCREAS CANCER; PRECANCER; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA, NEOPLASM; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RNA, NEOPLASM;

EID: 70350599558     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.107     Document Type: Review

References (163)

1. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 128(6), 1606-1625 (2005). (Pubitemid 40692555)
2. Kern SE, Hruban RH, Hidalgo M, Yeo CJ. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol. Ther. 1(6), 607-613 (2002).
3. Yeo TP, Hruban RH, Leach SD et al. Pancreatic cancer. Curr. Probl. Cancer 26(4), 176-275 (2002).
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
5. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 56(8), 1134-1152 (2007). • Good overview of molecular and clinical aspects of pancreatic cancer.
6. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol. 25(18), 2607-2615 (2007). (Pubitemid 47041235)
7. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431(7011), 931-945 (2004).
8. Harada T, Baril P, Gangeswaran R et al. Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation. Br. J. Cancer 96(2), 373-382 (2007). (Pubitemid 46160645)
9. Harada T, Chelala C, Bhakta V et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27(13), 1951-1960 (2008).
10. Holzmann K, Kohlhammer H, Schwaenen C et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 64(13), 4428-4433 (2004). (Pubitemid 38856913)
11. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008). •• Comprehensive study of molecular changes in pancreatic cancer using different technological platforms; identification of 12 'core signaling pathways' relevant in pancreatic cancer.
12. Nowak NJ, Gaile D, Conroy JM et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 161(1), 36-50 (2005).
13. Gress TM, Muller-Pillasch F, Geng M et al. A pancreatic cancer-specific expression profile. Oncogene 13(8), 1819-1830 (1996).
14. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62(10), 2890-2896 (2002). (Pubitemid 34525776)
15. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20(50), 7437-7446 (2001). (Pubitemid 33078216)
16. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21(29), 4587-4594 (2002). (Pubitemid 34785735)
17. Iacobuzio-Donahue CA, Maitra A, Olsen M et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 162(4), 1151-1162 (2003). (Pubitemid 36350660)
18. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160(4), 1239-1249 (2002). (Pubitemid 34411628)
19. Buchholz M, Braun M, Heidenblut A et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24(44), 6626-6636 (2005). (Pubitemid 41486793)
20. Grutzmann R, Foerder M, Alldinger I et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch. 443(4), 508-517 (2003). (Pubitemid 37363377)
21. Grutzmann R, Pilarsky C, Ammerpohl O et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6(5), 611-622 (2004). (Pubitemid 39411099)
22. Jin G, Hu XG, Ying K et al. Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays. World J. Gastroenterol. 11(41), 6543-6548 (2005). (Pubitemid 43136897)
23. Logsdon CD, Simeone DM, Binkley C et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63(10), 2649-2657 (2003). (Pubitemid 36605209)
24. Nakamura T, Furukawa Y, Nakagawa H et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23(13), 2385-2400 (2004). (Pubitemid 38496794)
25. Prasad NB, Biankin AV, Fukushima N et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 65(5), 1619-1626 (2005). (Pubitemid 40478583)
26. Friess H, Ding J, Kleeff J et al. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell. Mol. Life Sci. 60(6), 1180-1199 (2003). (Pubitemid 36791920)
27. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17), 1901-1908 (2007).
28. Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046-1054 (2007). (Pubitemid 46214304)
29. Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007). (Pubitemid 47014466)
30. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129(5), 1454-1463 (2005). (Pubitemid 41597388)
31. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol. Cell. Proteomics 4(4), 523-533 (2005). (Pubitemid 40590569)
32. Chen R, Yi EC, Donohoe S et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129(4), 1187-1197 (2005). (Pubitemid 41446859)
33. Shekouh AR, Thompson CC, Prime W et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3(10), 1988-2001 (2003).
34. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64(24), 9018-9026 (2004). (Pubitemid 39665512)
35. Sato N, Fukushima N, Hruban RH, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 21(3), 238-244 (2007). (Pubitemid 351304281)
36. Sato N, Goggins M. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J. Hepatobiliary Pancreat. Surg. 13(4), 280-285 (2006). (Pubitemid 44111335)
37. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 11(13), 4681-4688 (2005). (Pubitemid 41557185)
38. Ueki T, Toyota M, Skinner H et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 61(23), 8540-8546 (2001). (Pubitemid 33131137)
39. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 16(10), 996-1006 (2003). (Pubitemid 37280815)
40. Hruban RH, Adsay NV, Bores-Saavedra J et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25(5), 579-586 (2001). •• Original paper on the consensus definition of pancreatic intraepithelial neoplasia lesions.
41. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin. Cancer Res. 6(8), 2969-2972 (2000). • First formal description of the linear progression model for pancreatic cancer.
42. Luttges J, Galehdari H, Brocker V et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am. J. Pathol. 158(5), 1677-1683 (2001). (Pubitemid 32422932)
43. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 12(2), 81-91 (2005).
44. Kloppel G, Luttges J. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr. Gastroenterol. Rep. 6(2), 111-118 (2004). (Pubitemid 38915057)
45. Luttges J, Kloppel G. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities. Dig. Dis. 19(1), 15-23 (2001). (Pubitemid 32506988)
46. Brembeck FH, Schreiber FS, Deramaudt TB et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 63(9), 2005-2009 (2003).
47. Hingorani SR, Petricoin EF, Maitra A et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6), 437-450 (2003). • First report of a K-ras transgenic mouse model recapitulating the morphological features of the human disease. (Pubitemid 38050041)
48. Hingorani SR, Wang L, Multani AS et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5), 469-483 (2005). (Pubitemid 40719130)
49. Aguirre AJ, Bardeesy N, Sinha M et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17(24), 3112-3126 (2003). (Pubitemid 38040774)
50. Parsa I, Longnecker DS, Scarpelli DG, Pour P, Reddy JK, Lefkowitz M. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer Res. 45(3), 1285-1290 (1985). (Pubitemid 15111293)
51. Wagner M, Greten FR, Weber CK et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15(3), 286-293 (2001). (Pubitemid 32155144)
52. G12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res. 66(1), 242-247 (2006).
53. Guerra C, Schuhmacher AJ, Canamero M et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11(3), 291-302 (2007). • A mouse model demonstrating the powerful influence of the microenvironment and the important role of inflammation for the development of pancreatic tumors. (Pubitemid 46349841)
54. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3), 313-323 (2007). (Pubitemid 47355323)
55. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67(3), 1030-1037 (2007). (Pubitemid 46270758)
56. Miyamoto Y, Maitra A, Ghosh B et al. Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6), 565-576 (2003). (Pubitemid 36808651)
57. Apelqvist A, Li H, Sommer L et al. Notch signalling controls pancreatic cell differentiation. Nature 400(6747), 877-881 (1999). (Pubitemid 29406724)
58. De La OJ, Murtaugh LC. Notch signaling: where pancreatic cancer and differentiation meet? Gastroenterology 136(5), 1499-1502 (2009).
59. Miyamoto Y, Maitra A, Ghosh B et al. Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6), 565-576 (2003). (Pubitemid 36808651)
60. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl Acad. Sci. USA 100(25), 14920-14925 (2003).
61. Kayed H, Kleeff J, Keleg S et al. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int. J. Cancer 110(5), 668-676 (2004). (Pubitemid 38746024)
62. Pasca di MM, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev. 20(22), 3161-3173 (2006). (Pubitemid 44790630)
63. Thayer SP, di Magliano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425(6960), 851-856 (2003).
64. Lowy AM, Fenoglio-Preiser C, Kim OJ et al. Dysregulation of β-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann. Surg. Oncol. 10(3), 284-290 (2003). (Pubitemid 40486962)
65. Pasca di MM, Biankin AV, Heiser PW et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS. ONE 2(11), 1155 (2007).
66. Al-Aynati MM, Radulovich N, Riddell RH, Tsao MS. Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia. Clin. Cancer Res. 10(4), 1235-1240 (2004). (Pubitemid 38365212)
67. Pujal J, Capella G, Real FX. The Wnt pathway is active in a small subset of pancreas cancer cell lines. Biochim. Biophys. Acta 1762(1), 73-79 (2006). (Pubitemid 43021089)
68. Ripka S, Konig A, Buchholz M et al. WNT5A - target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28(6), 1178-1187 (2007). (Pubitemid 47062676)
69. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4), 549-554 (1988).
70. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int. J. Pancreatol. 18(1), 1-6 (1995).
71. Seufferlein T, Van LJ, Liptay S, Adler G, Schmid RM. Transforming growth factor α activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 116(6), 1441-1452 (1999). (Pubitemid 29258893)
72. Pugliese V, Pujic N, Saccomanno S et al. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest. Endosc. 54(5), 595-599 (2001). (Pubitemid 33666031)
73. Van Laethem JL, Bourgeois V, Parma J et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest. Endosc. 47(6), 479-485 (1998). (Pubitemid 28287566)
74. Luttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Kloppel G. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85(8), 1703-1710 (1999). (Pubitemid 29169670)
75. Sherr CJ. Principles of tumor suppression. Cell 116(2), 235-246 (2004).
76. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57(9), 1731-1734 (1997).
77. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8(1), 27-32 (1994). (Pubitemid 24274057)
78. Wilentz RE, Geradts J, Maynard R et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 58(20), 4740-4744 (1998). (Pubitemid 28480644)
79. Sohn TA. The molecular genetics of pancreatic ductal carcinoma. Minerva Chir. 57(5), 561-574 (2002).
80. Massague J. TGFb in cancer. Cell 134(2), 215-230 (2008).
81. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271(5247), 350-353 (1996). (Pubitemid 3021510)
82. Zapatka M, Zboralski D, Radacz Y et al. Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. Oncogene 26(10), 1417-1427 (2007). (Pubitemid 46340807)
83. Duda DG, Sunamura M, Lefter LP et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22(44), 6857-6864 (2003). (Pubitemid 37386685)
84. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58(23), 5329-5332 (1998). (Pubitemid 28551110)
85. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
86. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85(1), 27-34 (2000).
87. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10), 2239-2245 (2000). (Pubitemid 30247122)
88. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13(1), 9-22 (1999). (Pubitemid 29038270)
89. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
90. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 10(10), 3327-3332 (2004). (Pubitemid 38685437)
91. Hoshida T, Sunamura M, Duda DG et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 25(2), 111-121 (2002). (Pubitemid 34815906)
92. Hotz HG, Hines OJ, Hotz B, Foitzik T, Buhr HJ, Reber HA. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J. Gastrointest. Surg. 7(2), 220-227 (2003). (Pubitemid 36875791)
93. Tokunaga T, Abe Y, Tsuchida T et al. Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int. J. Oncol. 21(5), 1027-1032 (2002).
94. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 62(7), 1996-2003 (2002).
95. Bocci G, Danesi R, Marangoni G et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur. J. Pharmacol. 498(1-3), 9-18 (2004). (Pubitemid 39208055)
96. Buchler P, Reber HA, Ullrich A et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 134(5), 772-782 (2003). (Pubitemid 37523962)
97. Solorzano CC, Baker CH, Bruns CJ et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. 16(5), 359-370 (2001).
98. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet 371(9630), 2101-2108 (2008).
99. Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology 8(4-5), 431-461 (2008).
100. Van CE, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231-2237 (2009).
101. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6), 1207-1218 (2006). (Pubitemid 44452768)
102. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 23(1-2), 74-79 (2006). (Pubitemid 44174844)
103. Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109(8), 1561-1569 (2007). (Pubitemid 46595692)
104. Lemoine NR, Hughes CM, Barton CM et al. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. 166(1), 7-12 (1992).
105. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J. Clin. Invest. 90(4), 1352-1360 (1992).
106. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). • First example of a successful molecular targeted biological agent in pancreatic cancer.
107. Van CE, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J. Clin. Oncol. 25(15), 1949-1952 (2007).
108. Semba S, Moriya T, Kimura W, Yamakawa M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 26(3), 250-257 (2003). (Pubitemid 36384157)
109. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 28(3), 353-358 (2004). (Pubitemid 38437337)
110. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21(2), 81-86 (1998). (Pubitemid 28122842)
111. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93(8), 3636-3641 (1996). (Pubitemid 26127592)
112. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1(12), 989-997 (2002).
113. Ito D, Fujimoto K, Mori T et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 118(9), 2337-2343 (2006).
114. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7(10), 3269-3275 (2001). (Pubitemid 32963853)
115. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60(19), 5451-5455 (2000). (Pubitemid 30761257)
116. Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 54(1), 109-116 (2005). (Pubitemid 40007228)
117. Altomare DA, Tanno S, De RA et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell Biochem. 87(4), 470-476 (2002).
118. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2, 10 (2003). (Pubitemid 38751487)
119. Matsubayashi H, Infante JR, Winter J et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol. Ther. 6(10), 1569-1575 (2007). (Pubitemid 351590328)
120. Merati K, Said SM, Andea A et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am. J. Clin. Oncol. 24(5), 447-452 (2001). (Pubitemid 32959100)
121. Yip-Schneider MT, Barnard DS, Billings SD et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21(2), 139-146 (2000).
122. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl Cancer Inst. 94(15), 1168-1171 (2002). (Pubitemid 34919054)
123. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20(4), 2625-2631 (2000).
124. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 1(4), 291-299 (2001).
125. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J. Pharmacol. Exp. Ther. 298(3), 976-985 (2001).
126. Sun WH, Chen GS, Ou XL et al. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor γ synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett. 275(2), 247-255 (2009).
127. Stoeltzing O, Liu W, Fan F et al. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett. 258(2), 291-300 (2007). (Pubitemid 350101026)
128. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63(4), 317-332 (2002).
129. Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48(10), 1972-1978 (2003).
130. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 20(57), 8203-8214 (2001).
131. Furuyama K, Doi R, Mori T et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J. Surg. 30(2), 219-226 (2006). (Pubitemid 43162494)
132. Sawai H, Okada Y, Funahashi H et al. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol. Cancer 4, 37 (2005). (Pubitemid 41574004)
133. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 135(5), 555-562 (2004). (Pubitemid 38586530)
134. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun. 311(3), 786-792 (2003). (Pubitemid 37377726)
135. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29(6), 1096-1107 (2008). (Pubitemid 351958687)
136. Menke A, Philippi C, Vogelmann R et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 61(8), 3508-3517 (2001). (Pubitemid 32695048)
137. Trevino JG, Summy JM, Gray MJ et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 65(16), 7214-7222 (2005).
138. Lutz MP, Esser IB, Flossmann-Kast BB et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 243(2), 503-508 (1998).
139. Kleespies A, Jauch KW, Bruns CJ. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist. Updat. 9(1-2), 1-18 (2006). (Pubitemid 43928802)
140. Yezhelyev MV, Koehl G, Guba M et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 10(23), 8028-8036 (2004). (Pubitemid 39587544)
141. Rajeshkumar NV, Tan AC, De Oliveira E et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15(12), 4138-4146 (2009).
142. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu. Rev. Physiol. 63, 49-76 (2001).
143. Smith JP, Shih A, Wu Y, McLaughlin PJ, Zagon IS. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am. J. Physiol. 270(5 Pt 2), R1078-R1084 (1996). (Pubitemid 26183789)
144. Caplin M, Savage K, Khan K et al. Expression and processing of gastrin in pancreatic adenocarcinoma. Br. J. Surg. 87(8), 1035-1040 (2000). (Pubitemid 30496852)
145. Smith JP, Stanley WB, Verderame MF, Zagon IS. The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer. Pancreas 29(4), 271-277 (2004).
146. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets. 12(4), 463-476 (2008).
147. Lee MA, Park GS, Lee HJ et al. Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 5, 127 (2005).
148. Qiao JG, Zhang YQ, Yin YC, Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J. Gastroenterol. 10(18), 2759-2761 (2004). (Pubitemid 39214520)
149. Kami K, Doi R, Koizumi M et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136(2), 443-448 (2004). (Pubitemid 39037686)
150. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br. J. Cancer 86(6), 886-892 (2002). (Pubitemid 34271023)
151. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92(2), 271-278 (2001). (Pubitemid 32664432)
152. Tonini G, Vincenzi B, Santini D et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br. J. Cancer 92(12), 2225-2232 (2005). (Pubitemid 40966261)
153. Guo Q, Chen Y, Zhang B, Kang M, Xie Q, Wu Y. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem. Pharmacol. 77(11), 1674-1683 (2009).
154. Asanuma K, Moriai R, Yajima T et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res. 91(11), 1204-1209 (2000).
155. Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle 6(13), 1553-1557 (2007).
156. Prasad NB, Biankin AV, Fukushima N et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 65(5), 1619-1626 (2005). (Pubitemid 40478583)
157. Heiser PW, Hebrok M. Development and cancer: lessons learned in the pancreas. Cell Cycle 3(3), 270-272 (2004). (Pubitemid 41359072)
158. Plentz R, Park JS, Rhim AD et al. Inhibition of γ-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136(5), 1741-1749 (2009).
159. Baeyens L, Bonne S, Bos T et al. Notch signaling as gatekeeper of rat acinar-to-β-cell conversion in vitro. Gastroenterology 136(5), 1750-1760 (2009).
160. Rooman I, De MN, Baeyens L et al. Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. Am. J. Pathol. 169(4), 1206-1214 (2006). (Pubitemid 351194357)
161. Stanger BZ, Stiles B, Lauwers GY et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3), 185-195 (2005). (Pubitemid 41317590)
162. Hernandez-Munoz I, Skoudy A, Real FX, Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8(4-5), 462-469 (2008).
163. Cadigan KM. Wnt-β-catenin signaling. Curr. Biol. 18(20), R943-R947 (2008).